Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer

Published:2014 Issue:3 Volume:16 Page:401
ISSN:1008-682X
Container-title:Asian Journal of Andrology
language:en
Short-container-title:Asian J Androl

Author:

Zhang Jingsong

Publisher

Medknow

Subject

Urology,General Medicine

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib, prevents acute lung injury associated cognitive deficits potentially through suppression of inflammatory response;European Journal of Pharmacology;2020-06

2. PLCε knockdown enhances the radiosensitivity of castration‑resistant prostate cancer via the AR/PARP1/DNA‑PKcs axis;Oncology Reports;2020-02-26

3. Circulating tumor cells and γH2AX as biomarkers for responsiveness to radium-223 in advanced prostate cancer patients;Future Science OA;2020-01-01

4. Proteomic Characterization of Prostate Cancer to Distinguish Nonmetastasizing and Metastasizing Primary Tumors and Lymph Node Metastases;Neoplasia;2018-02

5. PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers;Gynecologic Oncology Research and Practice;2017-11-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP